0001477932-22-007378.txt : 20220930 0001477932-22-007378.hdr.sgml : 20220930 20220930170020 ACCESSION NUMBER: 0001477932-22-007378 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220929 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220930 DATE AS OF CHANGE: 20220930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UPEXI, INC. CENTRAL INDEX KEY: 0001775194 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 833378978 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40535 FILM NUMBER: 221284766 BUSINESS ADDRESS: STREET 1: 17129 US HWY 19 N. CITY: CLEARWATER STATE: FL ZIP: 33760 BUSINESS PHONE: 701-353-5425 MAIL ADDRESS: STREET 1: 17129 US HWY 19 N. CITY: CLEARWATER STATE: FL ZIP: 33760 FORMER COMPANY: FORMER CONFORMED NAME: GROVE, INC. DATE OF NAME CHANGE: 20190429 8-K 1 grvi_8k.htm FORM 8-K grvi_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

 

FORM 8-K

_________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 29, 2022

 

UPEXI, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-25526

 

83-3378978

(State or Other Jurisdiction

 of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

 Identification No.)

 

17129 US Hwy 19 N.

Clearwater, FL 33764

(Address of Principal Executive Offices) (Zip Code)

 

(701) 353-5425

(Registrant's telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001

 

UPXI

 

NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Section 2 – Financial Information

 

Item 2.02 Results of Operations and Financial Condition.

 

On September 29, 2022, Upexi, Inc. (the “Company”) issued a press release announcing financial and operational results and business highlights for the year ended June 30, 2022 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Form 8-K (including Exhibit 99.1) is being “furnished,” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referenche in such a filing.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.

Exhibit Description

99.1

Press Release of Upexi, Inc., dated September 29, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

UPEXI, INC.

 

 

 

 

 

Dated: September 30, 2022

 

/s/ Andrew J. Norstrud

 

 

 

Name: Andrew J. Norstrud

 

 

 

Title: Chief Financial Officer

 

 

 

3

 

 EX-99.1 2 grvi_ex991.htm PRESS RELEASE grvi_ex991.htm

EXHIBIT 99.1

 

 

 

Upexi Revenue Increases 85% Year-Over-Year to

$44.6 Million for Fiscal 2022

 

HENDERSON, NV, September 29, 2022 (GLOBE NEWSWIRE) – Upexi, Inc. (NASDAQ: UPXI), a multi-faceted brand owner, today announced its financial results for the fiscal year ending June 30, 2022.

 

Fiscal 2022 Financial Highlights:

 

 

·

 Revenue totaled $44.6 million, an increase of 85% year-over-year.

 

 

 

 

·

 Pro forma, unaudited revenue for fiscal 2022 totaled $68 million (reconciliation below).

 

 

 

 

·

 Gross profit totaled $25.2 million, an increase of 112% year-over-year.

 

 

 

 

·

 Gross profit margin improved to 56% as compared to 49% in fiscal 2021.

 

 

 

 

·

 Adjusted EBITDA totaled $3.4 million, an increase of 6.7% year-over-year (reconciliation below).

 

 

 

 

·

 GAAP Net Loss totaled $2.1 million as compared to net income of $2.9 million in fiscal 2021, primarily due to non-cash expenses.

 

 

 

 

·

 Cash and cash equivalents totaled $7.2 million as of June 30, 2022.

 

Allan Marshall, Chief Executive Officer of Upexi, stated, “During the 2022 fiscal year we successfully executed on our business model to acquire leading, profitable, and data-rich brands to quickly integrate and scale through our technology-driven platform. As a result, we are pleased to have increased revenue, gross profit margin, and adjusted EBITDA year-over-year. We have had a strong start to the 2023 fiscal year with the acquisition of LuckyTail, a leading international, recession-resilient, pet-care brand. Following up on our recent successes, we expect to evaluate and close other accretive transactions throughout the upcoming year. We are well positioned through our recent successful acquisitions, strong cash flow, and the ability to use our equity as currency to execute our core strategy of aggregating leading brands to grow the company and build value for our shareholders.”

 

Operational Highlights for Fiscal 2022:

 

 

·

August 1, 2021: Completed an asset purchase agreement with the members of VitaMedica Corporation, a leading online seller of supplements for surgery, recovery, skin, beauty, health, and wellness.

 

 

 

 

·

October 1, 2021: Completed an equity interest purchase agreement, to acquire Interactive Offers, LLC, a SaaS, programmatic advertising company that has operated successfully in the fintech space for numerous years, with recent expansion into eCommerce to boost platform profits and growth.

 

 

 

 

·

April 1, 2022: Completed a securities purchase agreement to acquire majority ownership of Cygnet Online, LLC, a well-established secondary market seller on Amazon with over 1,200 SKUs of branded OTC products and supplements in health, wellness, and beauty verticals.

 

 

 

 

·

 May 2022: Launched the Cure Mushrooms brand in the U.S., an organic medicinal mushroom extract nutraceutical.

 

Operational Highlights Subsequent to Fiscal 2022 Full Year

 

 

·

 August 12, 2022: Completed an asset purchase agreement to acquire substantially all of the assets of LuckyTail, an international pet care brand with strong presence on Amazon and its eCommerce store, offering grooming and nutritional products.

 

Financial Highlights for Fiscal 2022

 

Revenue totaled $44.6 million, an increase of $20.5 million or 85% for the fiscal year ended June 30, 2022, compared with the fiscal year ended June 30, 2021. Approximately $15 million or 73% of the increase was related to the acquisition of VitaMedica, Interactive and Cygnet and $5.5 million or 23% was related to the core business compared to the prior year period. The core business increase was related to increased manufacturing and the Company’s own brands increase in direct to consumer sales.

 

Cost of revenue totaled $19.4 million, an increase of $7.2 million or 59% compared with the prior year. Approximately $6.8 million was related to the acquisition of VitaMedica, Interactive and Cygnet and $372,063 was related to the core business. Gross profit margin improved by 7% to 56%, compared to the prior year gross profit margin of 49%. The gross profit of the core business improved 9% to 58%, compared to the prior year. The gross margin improvement for the core business was primarily related to the consolidation of manufacturing, additional equipment purchased during the year, efficiency improvements in the manufacturing process and an increase in direct-to-consumer sales. Management expects to continue to improve gross margins as the Company consolidates acquisitions and controls direct costs.

 

 
1

 

 

Operating expenses totaled $27.9 million, an increase of $17.4 million or 166% compared with the prior fiscal year. Approximately $7.8 million was related to the sales, marketing and general administrative expenses of the acquisition of VitaMedica, Interactive and Cygnet. The core business sales and marketing increased by $2.3 million due to the increased spending on marketing of direct-to-consumer products and the growth of the sales and marketing team to support the current and expected future sales and product growth. The core business general and administrative expenses increased $2.8 million due to increased infrastructure, acquisition costs and employee related costs. The core business, non-cash expenses of share-based compensation, amortization and depreciation, increased $4.4 million. The Company’s management is continuing to control operating expenses while also implementing management growth strategies.

 

Adjusted EBITDA for the fiscal year ended June 30, 2022 totaled $3.4 million, an increase of 6.7% as compared to $3.2 million for the fiscal year ended June 30, 2021.

 

The Company had a net loss of $2,046,030 compared to net income of $2,978,948 for the prior year. The change in net income primarily related to the $745,042 change of income tax benefit compared to the prior year and a $4,423,588 increase in non-cash expenses.

 

The Company writes-off the value of inventory deemed excessive or obsolete. The Company wrote off $1,044,607 and $375,000 of inventory during the year ended June 30, 2022, and 2021, respectively.

 

The Company has cash and cash equivalents of $7.2 million and stockholders’ equity of $28.8 million as of June 30, 2022. As of September 26, 2022 there were 16,713,345 shares of common stock outstanding.

 

Consolidated Pro Forma Unaudited Financial Statements

 

The following unaudited pro forma combined financial information is based on the historical financial statements of the Company, VitaMedica, Interactive and Cygnet after giving effect to the Company’s acquisitions of the companies as if the acquisitions occurred on July 1, 2021.

 

The following unaudited pro forma information does not purport to present what the Company’s actual results would have been had the acquisitions occurred on July 1, 2021, nor is the financial information indicative of the results of future operations. The following table represents the unaudited consolidated pro forma results of operations for the fiscal years ending June 30, 2022, as if the acquisition occurred on July 1, 2021. Operating expenses for the fiscal years ending June 30, 2022 have been increased for the amortization expense associated with the fair value adjustment of definite lived intangible assets of VitaMedica, Interactive and Cygnet by $1,767,350 .

 

Pro Forma, Unaudited

 

 

 

 

 

 

 

 

 

Proforma

 

 

 

Year ended June 30, 2022

 

Upexi, Inc.

 

 

VitaMedica

 

 

Interactive

 

 

Cygnet

 

 

Adjustments

 

 

Proforma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

 $ 44,584,996

 

 

 $ 384,391

 

 

 $ 416,700

 

 

 $ 22,583,781

 

 

$

 

 

 $ 67,969,868

 

Cost of sales

 

 $ 19,396,123

 

 

 $ 93,509

 

 

 $ -

 

 

 $ 19,117,296

 

 

$

 

 

 $ 38,606,928

 

Operating expenses

 

 $ 27,841,203

 

 

 $ 255,286

 

 

 $ 795,507

 

 

 $ 2,086,722

 

 

 $ 1,767,350

 

 

 $ 32,746,068

 

Net income (loss)

 

 $ (2,046,030 )

 

 $ 35,596

 

 

 $ (378,807 )

 

 $ 1,117,971

 

 

 $ (1,767,350 )

 

 $ (3,038,620 )

Basic income (loss) per common share

 

 $ (0.13 )

 

 $ 0.36

 

 

 $ (0.68 )

 

 $ 2.01

 

 

$

 

 

 $ (0.17 )

Weighted average shares outstanding

 

 

 16,224,520

 

 

 

 100,000

 

 

 

 560,170

 

 

 

 555,489

 

 

 

 

 

 

 

 17,440,179

 

 

Revenue Guidance for Fiscal 2023

 

Management expects revenue to increase in the 2023 fiscal year through both organic growth of the core business, acquisitions completed during the 2022 fiscal year and additional strategic acquisitions that align with managements long-term growth strategies. For fiscal 2023, management estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.

 

 
2

 

 

About Upexi, Inc.:

 

Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year over year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house, SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.

 

FORWARD LOOKING STATEMENTS:

 

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

 

Reconciliation of Non-GAAP Adjusted EBITDA to GAAP Net Income (Net Loss)

Year Ended June 30,

 

 

 

 

 

 

 

2022

 

 

2021

 

Net income (Net loss) GAAP

 

 $ (2,046,030 )

 

 $ 2,978,948

 

Income tax

 

 

 (518,398 )

 

 

 (1,282,815 )

Interest expense, net

 

 

 215,300

 

 

 

 530,449

 

Depreciation and amortization

 

 

 2,733,455

 

 

 

 1,030,021

 

Stock compensation

 

 

 2,755,016

 

 

 

 611,432

 

Stock issued for services

 

 

 576,774

 

 

 

 127,500

 

Change in derivative liability

 

 

 3,293

 

 

 

 -

 

Gain on lease settlement

 

 

 -

 

 

 

 (387,860 )

Gain on SBA PPP loan forgiveness

 

 

 (300,995 )

 

 

 (403,277 )

Gain on sale of asset

 

 

 (5,500 )

 

 

 (8,708 )

Non-GAAP adjusted EBITDA

 

 $ 3,412,915

 

 

 $ 3,195,690

 

 

Use of Non-GAAP Financial Measures

 

The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to establish operational goals, for compensation plans, to measure debt service capability, for capital expenditure planning and to determine working capital needs and believes that these are useful financial measures also used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration & restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items. Non-GAAP EBITDA and non-GAAP adjusted EBITDA are not terms defined by GAAP and, as a result, the Company’s measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA might not be comparable to similarly titled measures used by other companies. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures discussed above, however, should be considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP, and as reflected on the Company’s financial statements prepared in accordance with GAAP. These non-GAAP financial measures are not a substitute for or presented in lieu of financial measures provided by GAAP and all measures and disclosures of financial information pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company’s financial results. The reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA to GAAP operating income (loss) and/or GAAP net income (net loss) referred to in the highlights or elsewhere are provided in the schedules that are a part of this document.

 

Company Contact

Andrew Norstrud, Chief Financial Officer

Email: andrew.norstrud@upexi.com

Phone: (702) 332-5591

 

Investor Relations Contact

KCSA Strategic Communications

Valter Pinto or Jack Perkins

Email: Upexi@KCSA.com

Phone: (212) 896-1254

 

 
3

 

 

UPEXI, INC.

CONSOLDIATED BALANCE SHEETS

 

 

 

June 30,

 

 

June 30,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

 $ 7,149,806

 

 

 $ 14,534,211

 

Accounts receivable, net of allowance for doubtful accounts of $57,500 and $45,000, respectively

 

 

 2,155,125

 

 

 

 1,277,662

 

Inventory

 

 

 6,454,428

 

 

 

 2,094,952

 

Deferred tax asset, current

 

 

 462,070

 

 

 

 -

 

Prepaid expenses and other receivables

 

 

 840,193

 

 

 

 386,258

 

Total current assets

 

 

 17,061,622

 

 

 

 18,293,083

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

 8,046,486

 

 

 

 2,832,400

 

Intangible assets, net

 

 

 12,052,020

 

 

 

 1,845,166

 

Goodwill

 

 

 8,301,206

 

 

 

 2,413,813

 

Deferred tax asset

 

 

 2,002,759

 

 

 

 1,403,591

 

Other assets

 

 

 100,372

 

 

 

 49,068

 

Right-of-use asset

 

 

 926,570

 

 

 

 417,443

 

Total other assets

 

 

 31,429,413

 

 

 

 8,961,481

 

 

 

 

 

 

 

 

 

 

Total assets

 

 $ 48,491,035

 

 

 $ 27,254,564

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

 $ 2,591,149

 

 

 $ 1,604,723

 

Accrued compensation

 

 

 556,547

 

 

 

 1,020,936

 

Deferred revenue

 

 

 335,205

 

 

 

 485,973

 

Accrued liabilities

 

 

 952,249

 

 

 

 296,021

 

Acquisition payable

 

 

 -

 

 

 

 1,764,876

 

Current portion of notes payable

 

 

 5,424,752

 

 

 

 447,100

 

Current portion of operating lease payable

 

 

 267,846

 

 

 

 199,532

 

Total current liabilities

 

 

 10,127,748

 

 

 

 5,819,161

 

 

 

 

 

 

 

 

 

 

Notes payable, net of current portion

 

 

 8,876,132

 

 

 

 -

 

Operating lease payable, net of current portion

 

 

 700,411

 

 

 

 217,430

 

Total long-term liabilities

 

 

 9,576,543

 

 

 

 217,430

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 -

 

 

 

 -

 

 

 

 

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 100,000,000 shares authorized, and 500,000 and 500,000 shares issued and outstanding, respectively

 

 

 500

 

 

 

 500

 

Common stock, $0.001 par value, 100,000,000 shares authorized, and 16,713,345 and 15,262,394 shares issued and outstanding, respectively

 

 

 16,713

 

 

 

 15,262

 

Additional paid in capital

 

 

 34,985,597

 

 

 

 25,372,247

 

Accumulated deficit

 

 

 (6,270,886 )

 

 

 (4,170,036 )

Total stockholders' equity attributable to Upexi, Inc.

 

 

 28,731,924

 

 

 

 21,217,973

 

Non-controlling interest in subsidiary

 

 

 54,820

 

 

 

 -

 

Total stockholders' equity

 

 

 28,786,744

 

 

 

 21,217,973

 

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' equity

 

 $ 48,491,035

 

 

 $ 27,254,564

 

 

 
4

 

 

UPEXI, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

Year Ended June 30,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

Revenue

 

 $ 44,584,996

 

 

 $ 24,095,025

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

 19,396,123

 

 

 

 12,196,123

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 25,188,873

 

 

 

 11,898,902

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Sales and marketing

 

 

 7,628,932

 

 

 

 2,388,211

 

General and administrative expenses

 

 

 14,147,230

 

 

 

 6,442,501

 

Share-based compensation

 

 

 3,331,586

 

 

 

 611,432

 

Amortization of acquired intangible assets

 

 

 2,159,146

 

 

 

 726,525

 

Depreciation

 

 

 574,309

 

 

 

 303,496

 

 

 

 

 27,841,203

 

 

 

 10,472,165

 

 

 

 

 

 

 

 

 

 

(Loss) income from operations

 

 

 (2,652,330 )

 

 

 1,426,737

 

 

 

 

 

 

 

 

 

 

Other expense (income), net

 

 

 

 

 

 

 

 

Interest expense (income), net

 

 

 215,300

 

 

 

 530,449

 

Gain on sale of assets

 

 

 (5,500 )

 

 

 (8,708 )

Gain on SBA PPP loan forgiveness

 

 

 (300,995 )

 

 

 (403,277 )

Change in derivative liability

 

 

 3,293

 

 

 

 -

 

Settlement of cancelled lease

 

 

 -

 

 

 

 (387,860 )

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

 

 (87,902 )

 

 

 (269,396 )

 

 

 

 

 

 

 

 

 

(Loss) income before income tax

 

 

 (2,564,428 )

 

 

 1,696,133

 

 

 

 

 

 

 

 

 

 

Income tax (expense) benefit

 

 

 518,398

 

 

 

 1,282,815

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

 

 (2,046,030 )

 

 

 2,978,948

 

 

 

 

 

 

 

 

 

 

Net loss attributable to noncontrolling interest

 

 

 (54,820 )

 

 

 -

 

Deemed dividend related to the issuance of Series A Preferred Stock

 

 

 -

 

 

 

 (50,000 )

 

 

 

 

 

 

 

 

 

Net (loss) income attributable to Upexi, Inc.

 

 $ (2,100,850 )

 

 $ 2,928,948

 

 

 

 

 

 

 

 

 

 

Basic (loss) income per share

 

 $ (0.13 )

 

 $ 0.25

 

 

 

 

 

 

 

 

 

 

Diluted (loss) income per share

 

 $ (0.13 )

 

 $ 0.21

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 16,224,520

 

 

 

 11,930,378

 

 

 

 

 

 

 

 

 

 

Fully diluted weighted average shares outstanding

 

 

 16,224,520

 

 

 

 14,257,934

 

 

 
5

 

 

UPEXI, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

 

 

 

Year Ended June 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities

 

 

 

 

 

 

Net (loss) income

 

 $ (2,046,030 )

 

 $ 2,978,948

 

Adjustments to reconcile net (loss) income to net cash provided by

 

 

 

 

 

 

 

 

operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

 2,733,455

 

 

 

 1,030,021

 

Inventory write-offs

 

 

 1,044,607

 

 

 

 375,000

 

Gain on settlement of cancelled lease

 

 

 -

 

 

 

 (387,860 )

Gain on change in deferred tax allowance

 

 

 (1,061,238 )

 

 

 (1,282,815 )

Amortization of beneficial conversion feature on convertible notes

 

 

 

 

 

 

 342,813

 

Shares issued for services

 

 

 -

 

 

 

 127,500

 

Bad debt expense

 

 

 131,968

 

 

 

 78,185

 

Gain on sale of equipment

 

 

 (5,500 )

 

 

 (8,708 )

Gain on forgiveness of SBA PPP loan

 

 

 (300,995 )

 

 

 (403,277 )

Stock based compensation

 

 

 3,331,586

 

 

 

 611,432

 

Changes in assets and liabilities, net of acquired amounts

 

 

 

 

 

 

 

 

Accounts receivable

 

 

 (17,312 )

 

 

 (1,138,228 )

Inventory

 

 

 (2,447,038 )

 

 

 (846,659 )

Prepaid expenses and other assets

 

 

 217,824

 

 

 

 (313,206 )

Accounts payable and accrued liabilities

 

 

 (430,506 )

 

 

 1,966,806

 

Accrued liabilities related to acquisition

 

 

 -

 

 

 

 (90,876 )

Deferred revenue

 

 

 (629,153 )

 

 

 (99,770 )

Net cash provided by operating activities

 

 

 521,872

 

 

 

 2,939,306

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

Acquisition of Infusionz, Inc., net of cash acquired

 

 

 -

 

 

 

 62,122

 

Acquisition of VitaMedica, Inc., net of cash acquired

 

 

 (2,574,589 )

 

 

 -

 

Acquisition of Interactive Offers, Inc., net of cash acquired

 

 

 (1,854,193 )

 

 

 -

 

Acquisition of Cygnet, Inc., net of cash acquired

 

 

 (1,028,763 )

 

 

 -

 

Proceeds from sale of property and equipment

 

 

 6,000

 

 

 

 79,000

 

Acquisition of property and equipment

 

 

 (6,154,476 )

 

 

 (1,422,129 )

Net cash used in investing activities

 

 

 (11,606,021 )

 

 

 (1,281,007 )

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock

 

 

 -

 

 

 

 10,950,315

 

Stock repurchase program

 

 

 (1,975,888 )

 

 

 -

 

Proceeds from issuance of preferred stock

 

 

 -

 

 

 

 50,000

 

Proceeds from issuance of related party note payable

 

 

 -

 

 

 

 750,000

 

Repayment of related party note payable

 

 

 -

 

 

 

 (750,000 )

Payment of note payable

 

 

 (1,002,874 )

 

 

 (12,000 )

Proceeds from issuance of notes payable

 

 

 6,678,506

 

 

 

 1,000,080

 

Net cash provided by financing activities

 

 

 3,699,744

 

 

 

 11,988,395

 

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash

 

 

 (7,384,405 )

 

 

 13,646,694

 

Cash, beginning of period

 

 

 14,534,211

 

 

 

 887,517

 

Cash, end of period

 

 $ 7,149,806

 

 

 $ 14,534,211

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow disclosures

 

 

 

 

 

 

 

 

Interest paid

 

 $ 64,460

 

 

 $ -

 

Income tax paid

 

 $ 656,000

 

 

 $ -

 

Issuance of common stock for acquisition of Infusionz

 

 $ 1,764,876

 

 

 $ 650,255

 

Issuance of common stock for conversion of notes payable and accrued interest

 

 $ 482,000

 

 

 $ 3,085,273

 

Repayment of Infusionz LLC debt to Upexi, Inc.

 

 $ -

 

 

 $ 72,000

 

Liabilities assumed from acquisition of Infusionz

 

 $ -

 

 

 $ (680,480 )

Liabilities assumed from acquisition of VitaMedica

 

 $ (309,574 )

 

 

 

 

Issuance of stock for acquisition of Interactive

 

 $ 2,733,628

 

 

 

 

 

Issuance of stock for acquisition of Cygnet

 

 $ 2,965,756

 

 

 

 

 

Liabilities assumed from acquisition of Cygnet

 

 $ 9,472,438

 

 

 

 

 

Stock issued for construction services

 

 $ 140,700

 

 

 $ -

 

 

 
6

 

 EX-101.SCH 3 upxi-20220929.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 upxi-20220929_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Ex Transition Period Entity Incorporation State Country Code Entity File Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Trading Symbol Security Exchange Name EX-101.CAL 5 upxi-20220929_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 upxi-20220929_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 upxi-20220929_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 grvi_ex991img1.jpg begin 644 grvi_ex991img1.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 29, 2022
Cover [Abstract]  
Entity Registrant Name UPEXI, INC.
Entity Central Index Key 0001775194
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Sep. 29, 2022
Entity Ex Transition Period false
Entity Incorporation State Country Code NV
Entity File Number 333-25526
Entity Tax Identification Number 83-3378978
Entity Address Address Line 1 17129 US Hwy 19 N
Entity Address City Or Town Clearwater
Entity Address State Or Province FL
Entity Address Postal Zip Code 33764
City Area Code 701
Local Phone Number 353-5425
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001
Trading Symbol UPXI
Security Exchange Name NASDAQ
XML 10 grvi_8k_htm.xml IDEA: XBRL DOCUMENT 0001775194 2022-09-29 2022-09-29 iso4217:USD shares iso4217:USD shares 0001775194 false 8-K 2022-09-29 UPEXI, INC. NV 333-25526 83-3378978 17129 US Hwy 19 N Clearwater FL 33764 701 353-5425 false false false false Common Stock, par value $0.001 UPXI NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://grvi.com/role/Cover Cover Cover 1 false false All Reports Book All Reports grvi_8k.htm grvi_ex991.htm upxi-20220929.xsd upxi-20220929_cal.xml upxi-20220929_def.xml upxi-20220929_lab.xml upxi-20220929_pre.xml http://xbrl.sec.gov/dei/2022 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "grvi_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "upxi-20220929_cal.xml" ] }, "definitionLink": { "local": [ "upxi-20220929_def.xml" ] }, "inline": { "local": [ "grvi_8k.htm" ] }, "labelLink": { "local": [ "upxi-20220929_lab.xml" ] }, "presentationLink": { "local": [ "upxi-20220929_pre.xml" ] }, "schema": { "local": [ "upxi-20220929.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "upxi", "nsuri": "http://grvi.com/20220929", "report": { "R1": { "firstAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "grvi_8k.htm", "contextRef": "From2022-09-29to2022-09-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://grvi.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "grvi_8k.htm", "contextRef": "From2022-09-29to2022-09-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://grvi.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001477932-22-007378-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-22-007378-xbrl.zip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end